Biologic and biosimilar treatment for skin conditions

The word biologics means any product made from living things such as plants or animals. This includes lots of different types of products, such as vaccines or blood products.

Biologics used as skin treatments are medicines used for long term (chronic) skin conditions. These biologics are made from protein and are grown from animal, human, or micro-organic material in a laboratory.

In skin conditions some parts of the body’s immune system can cause skin conditions by overreacting or working without need. Biologics work by stopping, or switching off, a small part of the immune system. Biologics do this by acting like substances naturally made in the body by the immune system. Sometimes biologics are referred to as targeted immunosuppressants.

Biosimilars can be thought of as copies of Biologics. Making biologics is complex, and it is difficult to make exact copies. Research so far has shown that biosimilars work as well as biologics. Biosimilars have been used in Europe since 2006.

The skin conditions treated by biologics and biosimilars include

• Psoriasis.
• Eczema.
• Hidradenitis Suppurativa.
• Urticaria.

When a biologic or biosimilar is made, the drug company that makes it will name the skin conditions that these products can be used for, and how to use them. This is called the drug license.

Sometimes dermatologists (skin doctors) use biologics or biosimilars for skin conditions that the drug company did not make them for. This is called off license use.

The dermatologist will have looked at the best evidence about treatments for this skin condition, before deciding to use them. Sometimes, for some people, the best treatment will be a biologic or biosimilar. The dermatologist has to ask for funding to use biologics or biosimilars off license. This is called an Individual Funding Request (or IFR) and it is the Clinical Commisioning group (CCG) who decide if it will be funded.

Usually, people with severe psoriasis or urticaria, or people with moderate to severe Hidradenitis Suppurativa or eczema, can have biologic or biosimilar treatment.

The National Institute for Health and Care Excellence (NICE) gives information to the NHS about when biologics or biosimilars should be used. This information can be looked at by anyone on the NICE website (see the end of the article for the NICE website address).

NICE advises that, before an NHS doctor or dermatologist uses a biologic or biosimilar:

• Other treatments (usually tablets) need to have been tried first.
• The skin condition needs to have had a big effect on someone’s ‘quality of life’.
• It needs to be severe (or moderate to severe in Hidradenitis Suppurativa and eczema).

Dermatologists measure how severe skin conditions are by using a written tool. For example, psoriasis is measured by the PASI score; eczema by the EASI score; urticaria by the UAS7 score; and Hidradenitis Suppurativa by the Hurley or HS-PGA score. Photographs are often also used with Hidradenitis Suppurativa. The effect of a skin condition on someone’s quality of life is measured with the DLQI tool: this is a questionnaire that patients fill in.

Your dermatologist or dermatology Clinical Nurse Specialist (CNS) will decide with you if a biologic or biosimilar is the right treatment for you. They will look at your skin condition using an assessment tool, to make sure that a biologic or biosimilar is the right thing for you according to NICE advice. They may need you to have screening tests to check the biologic or biosimilar is safe for you, such as blood tests and a chest X-ray.

The dermatologist will prescribe the biologic or biosimilar (if they know NICE will advise you should have them; if your screening tests are OK; and if you agree you want to have them).

The dermatologist or CNS will also complete a registration form. This is a form with your name, contact details, diagnosis, weight, and allergies. For the biologic called Infliximab, a registration form is not used.

The biologic or biosimilar prescription and registration form is sent through to the Brighton and Sussex University Hospital pharmacy team who forward it to a homecare company. On your biologic consent form you will be asked to consent for the passing of your details to the healthcare companies prior to us sharing them. The homecare company then log the prescription with their pharmacy and arrange a delivery of the drug to you. They will contact you using the details on the registration form to arrange a convenient day and time.

Examples of homecare companies are Health Care at Home, HealthNet Homecare and Lloyds Pharmacy Homecare.

Biologics and biosimilars need to be stored in a fridge: this is a normal domestic fridge that you keep your food in. Do not store the injections next to raw meat or fish. Avoid the injection boxes becoming frozen or wet. It is important that your fridge is in good working order as biologics/ biosimilars are expensive and should not be wasted because of a faulty fridge. If you have a problem with your fridge please contact your pharmacist, dermatologist or dermatology nurse to see if your injection can still be used.

The homecare company will also arrange a nurse from their company to show you how to inject yourself if you need to learn how to do this. They will also give you some advice about using biologics. For the biologic called Ustekinumab the nurse will arrange with you to come to your home to give the injection every time.

Most biologics or biosimilars are given as a small injection just under the skin. For most biologics or biosimilars you are taught how to give this injection yourself.

A nurse comes to your home to show you how to self inject. A nurse will come to your home and give you the injection if you are prescribed a biologic called Ustekinumab. Another biologic, called Infliximab, is given by a drip (infusion) in the hospital, usually every 6-8 weeks.

The biologic or biosimilar injections that you inject yourself with can come in a pre-filled syringe or in an easy to use pen-like device. How often you inject yourself depends on the biologic or biosimilar prescribed. Some can be as often as twice a week and some only once every twelve weeks.